Press release: STADA continues strong growth journey in the first half of 2024
One document
more
Stories from Bad
- Language:
- Media:
- Period:
- Period:Total
Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorePress release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
One documentmorePress release: STADA continues with double-digit sales and profit growth in 2023
One documentmorePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmorePress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
One documentmore- 3
Press release: STADA further improves Sustainability ranking; rates among top 6% of pharma players globally
One documentmore Press release: STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio
One documentmore- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore - 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore Press release : STADA further grows its European Consumer Healthcare portfolio by acquiring several additional brands from Sanofi
One documentmorePress release: STADA appoints Christos Gallis as Head of Eastern Europe
One documentmorePress release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
One documentmorePress release: STADA sustains strong momentum with double-digit sales and profit growth in 2022
One documentmorePress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
One documentmorePress release: Adalvo and STADA extend their strategic partnership
Adalvo and STADA extend their strategic partnership - Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes - Adalvo CEO Anil Okay: “These new agreements demonstrate the significance of the strategic partnership we have built with STADA, in the last couple of years. We take ...
One documentmorePress release: STADA appoints Boris Döbler as Chief Financial Officer
One documentmore- 3
Press release: STADA ranks among top 10% of pharma firms on sustainability
One documentmore Press release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
One documentmore- 3
Press release: STADA starts work on >EUR50m facility to strengthen European medicines supply
One documentmore Press release: Stéphane Jacqmin joins STADA from Sanofi and becomes Head of Emerging Markets
One documentmoreFresenius achieves record Q3 earnings - improves 2011 earnings outlook
Bad Homburg (ots) - Q1-3 2011: - Sales EUR 12.1 billion, +2% at actual rates, +5% in constant currency - EBIT EUR 1,862 million, +5% at actual rates, +9% in constant currency - Net income EUR 565 million, +14% at actual rates, +17% in constant currency - Fresenius improves 2011 earnings1 outlook of 15% ...
One documentmore
1